<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36834216</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1660-4601</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of environmental research and public health</Title><ISOAbbreviation>Int J Environ Res Public Health</ISOAbbreviation></Journal><ArticleTitle>Annual Direct Cost and Cost-Drivers of Systemic Lupus Erythematosus: A Multi-Center Cross-Sectional Study from CSTAR Registry.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3522</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijerph20043522</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To estimate the annual direct costs and cost-drivers associated with systemic lupus erythematosus (SLE) patients in China.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A multi-center, cross-sectional study was conducted based on the CSTAR registry. The information on demography and expenditures for outpatient and inpatient visits due to SLE were collected using online questionnaires. These patients' medical records were from the database of the Chinese Rheumatology Information System (CRIS). The average direct costs and 95% confidence interval were estimated using the bootstrap method with 1000 bootstrap samples by resampling with replacement. The cost-drivers were identified using multivariate regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1778 SLE patients from 101 hospitals participated in our study, with 92.58% as females, a mean age of 33.8 years old, a median duration of SLE of 4.9 years, 63.8% in an active disease state, 77.3% with two organs or more damaged, and 8.3% using biologics as treatment. The average annual direct cost per patient was estimated at CNY 29,727, which approximates to 86% for direct medical costs. For moderate to severe disease activities, the use of biologics, hospitalization, treatment of moderate or high dose glucocorticoids, and peripheral vascular, cardiovascular, and/or renal system involvements were found to substantially increase the direct costs, while health insurance slightly decreased the direct costs of SLE.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study provided reliable insight into financial pressures on individual SLE patients in China. The efforts focusing on preventing flare occurrences and limiting disease progression were recommended to further reduce the direct cost of SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp; School of Basic Medicine Peking Union Medical College, Beijing 100005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mengtao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Kaiwen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp; School of Basic Medicine Peking Union Medical College, Beijing 100005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yilin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp; School of Basic Medicine Peking Union Medical College, Beijing 100005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Qiaoling</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp; School of Basic Medicine Peking Union Medical College, Beijing 100005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp; School of Basic Medicine Peking Union Medical College, Beijing 100005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jiuliang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chanyuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Xinping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanhong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-3436-4673</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp; School of Basic Medicine Peking Union Medical College, Beijing 100005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2019-I2M-2-008, 2021-I2M-1-005</GrantID><Agency>CAMS Innovation Fund for Medical Sciences</Agency><Country/></Grant><Grant><GrantID>No. Z201100005520022,23, 25-27</GrantID><Agency>Beijing Municipal Science &amp; Technology Commission</Agency><Country/></Grant><Grant><GrantID>2022-PUMCH-B-013</GrantID><Agency>National High Level Hospital Clinical Research Funding</Agency><Country/></Grant><Grant><GrantID>2021YFC2501300</GrantID><Agency>the Chinese National Key Technology R&amp;D Program, Ministry of Science and Technology</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Environ Res Public Health</MedlineTA><NlmUniqueID>101238455</NlmUniqueID><ISSNLinking>1660-4601</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005102" MajorTopicYN="N">Health Expenditures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="Y">Biological Products</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">direct costs</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>2</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36834216</ArticleId><ArticleId IdType="pmc">PMC9963905</ArticleId><ArticleId IdType="doi">10.3390/ijerph20043522</ArticleId><ArticleId IdType="pii">ijerph20043522</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Segura B.T. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology. 2020;59:524&#x2013;533. doi: 10.1093/rheumatology/kez516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez516</ArticleId><ArticleId IdType="pmc">PMC8414923</ArticleId><ArticleId IdType="pubmed">31377781</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers S.A. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology. 2009;48:673&#x2013;675. doi: 10.1093/rheumatology/kep062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep062</ArticleId><ArticleId IdType="pubmed">19359343</ArticleId></ArticleIdList></Reference><Reference><Citation>Urowitz M.B. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res. 2012;64:132&#x2013;137. doi: 10.1002/acr.20648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20648</ArticleId><ArticleId IdType="pubmed">21954226</ArticleId></ArticleIdList></Reference><Reference><Citation>Nusbaum J.S. Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Considerations, and Disease Pathogenesis. Mayo. Clin. Proc. 2020;95:384&#x2013;394. doi: 10.1016/j.mayocp.2019.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2019.09.012</ArticleId><ArticleId IdType="pubmed">32029091</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant E.C. Systemic lupus erythematosus. Lancet. 2001;358:586. doi: 10.1016/S0140-6736(01)05731-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(01)05731-2</ArticleId><ArticleId IdType="pubmed">11526930</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X. The challenges and future perspective for the management of systemic lupus erythematosus in China: A concise annual report of 2020. Rheumatol. Immunol. Res. 2022;3:38&#x2013;44. doi: 10.2478/rir-2022-0006.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/rir-2022-0006</ArticleId><ArticleId IdType="pmc">PMC9524811</ArticleId><ArticleId IdType="pubmed">36467018</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgson T.A. Cost-of-illness methodology: A guide to current practices and procedures. Milbank Mem. Fund Q. Health. Soc. 1982;60:429&#x2013;462. doi: 10.2307/3349801.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/3349801</ArticleId><ArticleId IdType="pubmed">6923138</ArticleId></ArticleIdList></Reference><Reference><Citation>Murimi-Worstell I.B. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States. J. Rheumatol. 2021;48:385&#x2013;393. doi: 10.3899/jrheum.191187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.191187</ArticleId><ArticleId IdType="pubmed">32611669</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatoye F. Direct health system costs for systemic lupus erythematosus patients in Alberta, Canada. PLoS ONE. 2021;16:e0251409. doi: 10.1371/journal.pone.0251409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0251409</ArticleId><ArticleId IdType="pmc">PMC8104382</ArticleId><ArticleId IdType="pubmed">33961687</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki C. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: A retrospective claims database study. J. Med. Econ. 2020;23:786&#x2013;799. doi: 10.1080/13696998.2020.1740236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2020.1740236</ArticleId><ArticleId IdType="pubmed">32149541</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.Y. Direct medical costs and their predictors in South Korean patients with systemic lupus erythematosus. Rheumatol. Int. 2015;35:1809&#x2013;1815. doi: 10.1007/s00296-015-3344-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-015-3344-8</ArticleId><ArticleId IdType="pubmed">26254885</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarting A. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. Rheumatol. Ther. 2021;8:375&#x2013;393. doi: 10.1007/s40744-021-00277-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-021-00277-0</ArticleId><ArticleId IdType="pmc">PMC7991067</ArticleId><ArticleId IdType="pubmed">33544369</ArticleId></ArticleIdList></Reference><Reference><Citation>Samnaliev M. Health-care utilization and costs in adults with systemic lupus erythematosus in the United Kingdom: A real-world observational retrospective cohort analysis. Rheumatol. Adv. Pract. 2021;5:rkab071. doi: 10.1093/rap/rkab071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rap/rkab071</ArticleId><ArticleId IdType="pmc">PMC8493101</ArticleId><ArticleId IdType="pubmed">34622127</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias G. Clinical and financial burden of active lupus in Greece: A nationwide study. Lupus. 2016;25:1385&#x2013;1394. doi: 10.1177/0961203316642310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316642310</ArticleId><ArticleId IdType="pubmed">27055520</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu T.Y. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: A cost-of-illness study in Hong Kong. Rheumatology. 2009;48:564&#x2013;568. doi: 10.1093/rheumatology/kep031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep031</ArticleId><ArticleId IdType="pubmed">19269959</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu Y.M. Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: A Taiwan nationwide population-based study. Rheumatol. Int. 2016;36:1507&#x2013;1514. doi: 10.1007/s00296-016-3551-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-016-3551-y</ArticleId><ArticleId IdType="pubmed">27534653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu T.Y. Cost-of-illness studies in systemic lupus erythematosus: A systematic review. Arthritis Care Res. 2011;63:751&#x2013;760. doi: 10.1002/acr.20410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20410</ArticleId><ArticleId IdType="pubmed">21557530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Semin. Arthritis Rheum. 2020;50:526&#x2013;533. doi: 10.1016/j.semarthrit.2019.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.11.007</ArticleId><ArticleId IdType="pubmed">31852583</ArticleId></ArticleIdList></Reference><Reference><Citation>Akobundu E. Cost-of-illness studies: A review of current methods. Pharmacoeconomics. 2006;24:869&#x2013;890. doi: 10.2165/00019053-200624090-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-200624090-00005</ArticleId><ArticleId IdType="pubmed">16942122</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo A.L. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Ery-thematosus. Arthritis Care Res. 2020;72:1289&#x2013;1295. doi: 10.1002/acr.24023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24023</ArticleId><ArticleId IdType="pubmed">31282076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell C.F. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States. Lupus. 2022;31:202&#x2013;211. doi: 10.1177/09612033211073670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211073670</ArticleId><ArticleId IdType="pmc">PMC8988287</ArticleId><ArticleId IdType="pubmed">35060407</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria A. Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy. Clin. Exp. Rheumatol. 2015;33:375&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">26005879</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsen A. Total cost and cost predictors in systemic lupus erythematosus&#x2014;8-years follow-up of a Swedish inception cohort. Lupus. 2015;24:1248&#x2013;1256. doi: 10.1177/0961203315584812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315584812</ArticleId><ArticleId IdType="pubmed">25957301</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L. Treatment adherence and disease burden of individuals with rheumatic diseases admitted as outpatients to a large rheumatology center in Shanghai, China. Patient Prefer. Adherence. 2017;11:1591&#x2013;1601. doi: 10.2147/PPA.S144624.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PPA.S144624</ArticleId><ArticleId IdType="pmc">PMC5609799</ArticleId><ArticleId IdType="pubmed">29075106</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q. Analysis of the annual direct economic burden and influencing factors of patients with systemic lupus erythematosus in Anhui province. J. Bengbu Med. 2020;45:536&#x2013;540.</Citation></Reference><Reference><Citation>Desgagne A. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics. 1998;13:487&#x2013;497. doi: 10.2165/00019053-199813050-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-199813050-00002</ArticleId><ArticleId IdType="pubmed">10180748</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter J. Bootstrap confidence intervals: When, which, what? A practical guide for medical statisticians. Stat. Med. 2000;19:1141&#x2013;1164. doi: 10.1002/(SICI)1097-0258(20000515)19:9&lt;1141::AID-SIM479&gt;3.0.CO;2-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(20000515)19:9&lt;1141::AID-SIM479&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">10797513</ArticleId></ArticleIdList></Reference><Reference><Citation>National Bureau of Statistics of China.  [(accessed on 8 October 2022)]; Available online:  http://www.stats.gov.cn/tjsj/ndsj/2021/indexch.htm.</Citation></Reference><Reference><Citation>Tanaka Y. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. Int. J. Rheum. Dis. 2018;21:1609&#x2013;1618. doi: 10.1111/1756-185X.13363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13363</ArticleId><ArticleId IdType="pmc">PMC6585770</ArticleId><ArticleId IdType="pubmed">30146745</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter E. The global burden of SLE: Prevalence, health disparities and socioeconomic impact. Nat. Rev. Rheumatol. 2016;12:605&#x2013;620. doi: 10.1038/nrrheum.2016.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.137</ArticleId><ArticleId IdType="pubmed">27558659</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M. Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus. 2013;22:1192&#x2013;1199. doi: 10.1177/0961203313499086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313499086</ArticleId><ArticleId IdType="pubmed">23963101</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasitanon N. Predictors of survival in systemic lupus erythematosus. Medicine. 2006;85:147&#x2013;156. doi: 10.1097/01.md.0000224709.70133.f7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000224709.70133.f7</ArticleId><ArticleId IdType="pubmed">16721257</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarcon G.S. Systemic lupus erythematosus in three ethnic groups. XIV. Poverty, wealth, and their influence on disease activity. Arthritis Rheum. 2004;51:73&#x2013;77. doi: 10.1002/art.20085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20085</ArticleId><ArticleId IdType="pubmed">14872458</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel B.A. The GLADEL multinational Latin American prospective inception cohort of 1214 patients with systemic lupus erythematosus: Ethnic and disease heterogeneity among &#x201c;Hispanics&#x201d;. Medicine. 2004;83:1&#x2013;17. doi: 10.1097/01.md.0000104742.42401.e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000104742.42401.e2</ArticleId><ArticleId IdType="pubmed">14747764</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria A. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann. Rheum. Dis. 2014;73:154&#x2013;160. doi: 10.1136/annrheumdis-2012-202443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202443</ArticleId><ArticleId IdType="pubmed">23264339</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamashta M.A. The cost of care of systemic lupus erythematosus (SLE) in the UK: Annual direct costs for adult SLE patients with active autoantibody-positive disease. Lupus. 2014;23:273&#x2013;283. doi: 10.1177/0961203313517407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313517407</ArticleId><ArticleId IdType="pubmed">24356612</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: A real-world cohort study, United States, 2004&#x2013;2015. Lupus Sci. Med. 2021;8:e000503. doi: 10.1136/lupus-2021-000503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000503</ArticleId><ArticleId IdType="pmc">PMC8442098</ArticleId><ArticleId IdType="pubmed">34521733</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z. Long-term outcomes of patients with systemic lupus erythematosus: A Multicenter Cohort Study from CSTAR registry. Rheumatol. Immunol. Res. 2021;2:195&#x2013;202. doi: 10.2478/rir-2021-0025.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/rir-2021-0025</ArticleId><ArticleId IdType="pmc">PMC9524789</ArticleId><ArticleId IdType="pubmed">36465068</ArticleId></ArticleIdList></Reference><Reference><Citation>Huscher D. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann. Rheum. Dis. 2006;65:1175&#x2013;1183. doi: 10.1136/ard.2005.046367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.046367</ArticleId><ArticleId IdType="pmc">PMC1798296</ArticleId><ArticleId IdType="pubmed">16540552</ArticleId></ArticleIdList></Reference><Reference><Citation>Panopalis P. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum. 2008;59:1788&#x2013;1795. doi: 10.1002/art.24063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24063</ArticleId><ArticleId IdType="pmc">PMC2875149</ArticleId><ArticleId IdType="pubmed">19035422</ArticleId></ArticleIdList></Reference><Reference><Citation>Anghel L.A. Medication adherence and persistence in patients with autoimmune rheumatic diseases: A narrative review. Patient Prefer. Adherence. 2018;12:1151&#x2013;1166. doi: 10.2147/PPA.S165101.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PPA.S165101</ArticleId><ArticleId IdType="pmc">PMC6037147</ArticleId><ArticleId IdType="pubmed">30013327</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Sattar A.B. Determinants of medication non-adherence in Egyptian patients with systemic lupus erythematosus: Sharkia Governorate. Rheumatol. Int. 2015;35:1045&#x2013;1051. doi: 10.1007/s00296-014-3182-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-014-3182-0</ArticleId><ArticleId IdType="pubmed">25424491</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>